NCT04098302View on ClinicalTrials.gov

Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

June 28, 2024

Study Completion Date

June 28, 2024

Conditions
Alcohol Use Disorder
Interventions
DRUG

Dutasteride Capsules

1 mg/day oral dutasteride (2 x 0.5 mg capsules)

DRUG

Placebo Capsules

Placebo capsules with matching appearance as Dutasteride Capsules

Trial Locations (1)

06030

University of Connecticut Health Center, Farmington

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

UConn Health

OTHER

NCT04098302 - Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy | Biotech Hunter | Biotech Hunter